Diffuse large B-cell lymphoma
Conditions
Interventions
Zebutinib combined with rchop regimen treatment group:None
Sponsors
The First Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
Male
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed DLBCL by pathology; 2. MYD88 L265P and CD79B mutations; 3. Aged 18-70 years; 4. ECOG 0-2; 5. Obtain the informed consent signed by the patient or his family.
Exclusion criteria
Exclusion criteria: 1. Received systemic or local treatment including chemotherapy in the first three weeks; 2. Liver and kidney function: blood bilirubin > 2 mg/dl (35 umol/L), AST/ALT was more than 2 times of the upper limit of normal, serum creatinine was more than 177 umol/L, the creatinine clearance rate was less than 60 ml/min; 3. Normal heart function: EF <= 50%; 4. The expected survival time was less than 3 months; 5. Chronic or current active infectious diseases requiring systemic antibiotics, antifungal agents or antiviral therapy; 6. Other concurrent and uncontrollable factors are considered by the researchers to affect the medical status of patients participating in the study; 7. Psychiatric patients or other patients who are known or suspected to be unable to fully comply with the study protocol; 8. People living with HIV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS, Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete response rate;Overall survival;Objective response rate;safety; | — |
Countries
China
Contacts
Public ContactJie Jin/Wenjuan Yu
The First Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed